2025

• Forsgren, Elin; Jørgensen, Rasmus R. K.; Bentzen, Hans; Riise, Jon; Haaber, Jacob; Pasanen, Annika. (2025) Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial. HemaSphere
  Vitenskapelig artikkel

2024

• Jerkeman, Mats; Kolstad, Arne; Hutchings, Martin; Pasanen, Annika; Meriranta, Leo; Niemann, Carsten Utoft. (2024) MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Advances
  Vitenskapelig artikkel

2022

• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung; Delic-Sarac, Marina. (2022) Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology
  Vitenskapelig artikkel

2019

• Lockmer, Sandra; Østenstad, Bjørn; Hagberg, Hans; Holte, Harald; Wahlin, Björn Engelbrekt; Wader, Karin Fahl. (2019) Reply to M. Sorigue et al. Journal of Clinical Oncology
  Leserinnlegg

2018

• Jerkeman, Mats; Eskelund, Christian Winther; Hutchings, Martin; Räty, Riikka; Wader, Karin Fahl; Laurell, Anna. (2018) Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Haematology
  Vitenskapelig artikkel
• Lockmer, Sandra; Østenstad, Bjørn; Hagberg, Hans; Holte, Harald; Johansson, Ann-Sofie; Wahlin, Björn Engelbrekt. (2018) Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: Results from two Nordic lymphoma group trials with more than 10 years of follow-up. Journal of Clinical Oncology
  Vitenskapelig artikkel

2016

• Nahi, Hareth; Våtsveen, Thea Kristin; Lund, Johan; Heeg, Bart M.S.; Preiss, Birgitte; Alici, Evren. (2016) Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology
  Vitenskapelig artikkel

2015

• Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola. (2015) BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal
  Vitenskapelig artikkel
• Olsen, Oddrun Elise; Wader, Karin Fahl; Hella, Hanne; Mylin, Anne K.; Turesson, Ingemar; Nesthus, Ingerid. (2015) Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Communication and Signaling
  Vitenskapelig artikkel
• Kimby, Eva; Østenstad, Bjørn; Brown, Peter; Hagberg, Hans; Erlanson, Martin; Holte, Harald. (2015) Two courses of four weekly infusions of rituximab with or without interferon-α2a: Final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia and Lymphoma
  Vitenskapelig artikkel

2014

• Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.. (2014) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer Journal
  Vitenskapelig artikkel
• Slørdahl, Tobias Schmidt; Wader, Karin Fahl; Berntsen, Erik Magnus. (2014) Månedens billede. Ugeskrift for Læger
  Vitenskapelig artikkel

2012

• Wader, Karin Fahl; Fagerli, Unn-Merete; Børset, Magne; Lydersen, Stian; Hov, Håkon; Sundan, Anders. (2012) Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology
  Vitenskapelig artikkel

2011

• Yri, Olav Erich; Torfoss, Dag; Hungnes, Olav; Tierens, Anne; Waalen, Kristian; Nordøy, Tone. (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood
  Vitenskapelig artikkel
• Yri, Olav Erich; Torfoss, Dag; Hungnes, Olav; Østenstad, Bjørn; Ekanger, Roald; Wader, Karin Fahl. (2011) LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION. Annals of Oncology
  Sammendrag/Abstract
• Wader, Karin Fahl; Fagerli, Unn-Merete; Holt, Randi Utne; Børset, Magne; Sundan, Anders; Waage, Anders. (2011) Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters. European Journal of Haematology
  Vitenskapelig artikkel

2009

• Wader, Karin Fahl; Hov, H; Brede, G; Standal, T; Martina, KI; Borset, M. (2009) Syndecan-1 Mediates HGF/c-Met Endocytosis and Signaling in Myeloma Cells. Clinical Lymphoma & Myeloma
  Sammendrag/Abstract

2008

• Wader, Karin Fahl; Fagerli, Unn-Merete; Holt, Randi Utne; Størdal, Berit Fladvad; Børset, Magne; Sundan, Anders. (2008) Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. European Journal of Haematology
  Vitenskapelig artikkel
• Wader, Karin Fahl; Fagerli, Unn Merete; Holt, Randi Utne; Børset, Magne; Størdal, Berit Fladvad; Sundan, Anders. (2008) Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. European Journal of Haematology
  Vitenskapelig artikkel